Jack Anders - 17 Jun 2022 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: SVP, Finance and Principal Accounting Officer
Issuer ticker: RVMD
Reported as of: 17 Jun 2022
Net transaction value: -$7,206
SEC form: 4
Accepted by SEC: 22 Jun 2022, 17:01:40 UTC
Prior SEC filing: 21 Mar 2022
Next SEC filing: 02 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders

Key filing fact

Jack Anders filed Form 4 for Revolution Medicines, Inc. (RVMD) on 22 Jun 2022.

Key facts

This page summarizes Jack Anders's Form 4 filing for Revolution Medicines, Inc. (RVMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Jun 2022, 17:01.

Change

Previous filing in this sequence was filed on 21 Mar 2022.
Current net transaction value: -$7,206.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: $7,206
Shares: -406
Change %: -2%
Price: $17.75
Shares after: 20,405
Date: 17 Jun 2022
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

Footnote F2

Includes 936 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2022.

Footnote F3

Includes 15,964 RSUs.

SEC remarks

SVP, Finance and Principal Accounting Officer